Semaglutide (GLP-1) and Low-Dose Naltrexone for Weight Loss
Semaglutide From the start of the COVID-19 pandemic, obesity is apparent as a risk factor for severe COVID-19 illness. Recently, a study released by the Centers for Disease Control and Prevention (CDC) demonstrated just how nonlinear this relationship is. The vast majority (over 75%) of U.S. patients hospitalized with COVID-19 were overweight or had obesity. …
Semaglutide (GLP-1) and Low-Dose Naltrexone for Weight Loss Read More »
